What is Raynaud's (Raynaud's disease or Raynaud's phenomenon) syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Raynaud syndrome is a condition that should be managed by avoiding triggers, keeping extremities warm, and considering medications such as dihydropyridine-type calcium antagonists, like nifedipine, as first-line therapy for severe cases, as recommended by the most recent evidence 1.

Key Points

  • The condition is characterized by episodes of reduced blood flow to the extremities, particularly the fingers and toes, in response to cold temperatures or stress.
  • Affected areas typically turn white, then blue, and finally red as blood flow returns, often accompanied by pain, numbness, or tingling.
  • Management includes:
    • Avoiding triggers such as cold, trauma, stress, smoking, vibration injury, or certain drugs like bleomycin, clonidine, and ergot alkaloids 1.
    • Keeping extremities warm by wearing proper clothing, such as a coat, mittens, hat, dry insulated footwear, and hand and/or foot warmers.
    • Considering medications like dihydropyridine-type calcium antagonists, usually oral nifedipine, as first-line therapy for severe cases 1.
    • Using phosphodiesterase type 5 (PDE-5) inhibitors, which have been shown to improve Raynaud’s condition score, reduce daily frequency and duration of RP attacks 1.

Treatment Approach

  • Dihydropyridine-type calcium antagonists, like nifedipine, should be used as first-line therapy for SSc-RP 1.
  • PDE5 inhibitors should also be considered for treatment of SSc-RP, given their high level of evidence supporting their use 1.
  • Intravenous iloprost should be considered for severe SSc-RP following failure of oral therapy, although no new publications with higher level of evidence were identified 1.

From the Research

Overview of Raynaud Syndrome

Raynaud syndrome is a condition characterized by vasospasm of the digital arteries, resulting in transient, recurrent, and reversible constriction of peripheral blood vessels 2. It is a multifactorial vasospastic disorder that affects up to 5% of the general population 2.

Key Features

  • Characterized by a triphasic discoloration of the affected area, beginning with pallor, followed by cyanosis, and finally ending with erythema 2
  • Often associated with pain and can persist from several minutes to hours 2
  • Can be idiopathic or a clinical manifestation of an underlying illness 2
  • Triggers include emotional distress and low temperature 2

Management Strategies

  • Lifestyle modifications, such as avoiding cold temperatures, smoking cessation, and anxiety management, are first-line treatments 2
  • Pharmacological therapies, including:
    • Calcium channel blockers 3, 4, 5
    • Alpha-1 adrenoreceptor antagonists 2
    • Angiotensin-converting enzyme inhibitors 2
    • Nitric oxide 2
    • Prostaglandin analogs 2
    • Phosphodiesterase inhibitors 4, 6, 2
  • Other non-pharmacological interventions, such as digital sympathectomy, may be beneficial in cases of critical digital ischemia 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Raynaud's Syndrome: a neglected disease.

International angiology : a journal of the International Union of Angiology, 2016

Research

Advances in the treatment of Raynaud's phenomenon.

Vascular health and risk management, 2010

Research

Calcium channel blockers for primary Raynaud's phenomenon.

The Cochrane database of systematic reviews, 2016

Research

Pharmacotherapy Options in the Management of Raynaud's Phenomenon.

Current treatment options in rheumatology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.